STOCK TITAN

Celularity Inc (CELUW) SEC Filings, Jul-Aug 2025

CELUW NASDAQ

Welcome to our dedicated page for Celularity SEC filings (Ticker: CELUW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Celularity Inc.'s SEC filings document material events for a regenerative and cellular medicine company with listed common stock and public warrants, including CELUW. The filings describe warrant terms exercisable for one-tenth of a share of Class A common stock, capital-structure disclosures, material agreements, and operating and financial results.

Recent Form 8-K disclosures also cover governance and executive-compensation matters, finance leadership changes, clinical or regulatory updates, and shareholder or security-structure matters tied to Celularity's placental-derived cell therapy and biologics business.

Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Genting-affiliated entities and chairman Lim Kok Thay have increased and reorganised their economic stake in Celularity (CUSIP 151190204) via Amendment No. 6 to their Schedule 13D. Dragasac now holds 6.34 m Class A shares (23.8%). Resorts World Inc. Pte. Ltd. (RWI) holds no shares today but can acquire 4.10 m shares (13.3%) through warrants. Genting Berhad, which controls Dragasac and 50 % of RWI, may be deemed to own 10.44 m shares (33.9%). Including existing shares and newly issued warrants, Mr. Lim could control up to 14.14 m shares, equal to 41 % of the post-exercise base of 34.45 m shares.

Key transaction terms: (i) Extension of three secured loans (combined face value US$27 m minus OID) to 15 Feb 2026 under a 12 Feb 2025 binding term sheet; (ii) repricing of RWI’s existing 1.95 m warrants to US$2.844 (10 % discount to 24 Jul 2025 close) and issuance of a new 500 k warrant on identical terms; (iii) issuance of a US$6.812 m promissory note to Mr. Lim at 2 % interest, maturing 21 Mar 2026, coupled with a 3.70 m warrant at US$2.528 (20 % discount) exercisable for five years after CFIUS clearance (if required); (iv) a portion of Lim Note proceeds will retire the loan from C.V. Starr. No other material contracts were disclosed. The filing confirms no criminal or civil findings against the reporting persons in the past five years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

How many Celularity (CELUW) SEC filings are available on StockTitan?

StockTitan tracks 42 SEC filings for Celularity (CELUW), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Celularity (CELUW)?

The most recent SEC filing for Celularity (CELUW) was filed on August 5, 2025.